SEATTLE, Oct. 18, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of two new translational research assays in the company’s Vantage 3D product line at the American Society of Human Genetics (ASHG) Annual Meeting in Vancouver Canada:
- nCounter Vantage 3D DNA (SNV) Solid Tumor Panel
- nCounter Vantage 3D Protein Solid Tumor Signaling Pathways Panel
The two new panels can be combined with one another as well as with the nCounter Vantage RNA Panels to enable more comprehensive profiling of formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The nCounter Vantage 3D Solid Tumor portfolio provides a deeper understanding of genotype and phenotype in various solid tumor cancers by enabling multiplexed, digital analysis of combinations of DNA, RNA, fusion genes, proteins and phospho-proteins simultaneously in a single experiment. Researchers now have the ability to extract more biological information from the limited tissue available from each sample using just two FFPE slides. Designed for flexibility, the nCounter Vantage 3D Solid Tumor portfolio provides new ways for cancer researchers to apply 3D Biology technology.
The nCounter Vantage 3D Protein Solid Tumor Signaling Pathways Panel enables the identification of activation state through the measurement of total proteins and phospho-proteins from a single slice of FFPE tissue or from as little as 250 ng of protein from cell or tissue lysate. The protein solid tumor panel can be used in combination with nCounter Vantage 3D DNA Panels and nCounter Vantage 3D RNA Panels, or in combination with the 770 gene PanCancer Pathways Panel to provide comprehensive solid tumor profiling.
“Simultaneous measurement of DNA, RNA and proteins could change how we assess and treat cancer,” said Gordon B. Mills M.D. Ph.D., Professor and Chair of Systems Biology at MD Anderson Cancer Center. “This new 3D Biology platform allows for an efficient approach to overcome this hurdle, and the identification of new biomarkers and signatures from a single platform could provide key clinical insights that can lead to a more personalized approach to medicine. Importantly, this platform could rapidly move to the clinic, directly benefitting patients.”
“Identifying clinically actionable mutations that can be correlated with unique signatures and cell response is key to our biomarker discovery and signature development,” said E. Aubrey Thompson, Ph.D., Professor of Cancer Biology, Mayo Clinic. “In the past we would have had to run multiple assays to answer our research question. Now we can run a single analysis, saving time and precious FFPE samples.”
Many experiments involve measurements of DNA, RNA, and protein to determine the biological impact and correlation of genotypic and phenotypic changes. Traditionally, the analysis of all three biomolecules typically requires three separate platforms. This traditional approach has two important limitations: inefficient use of small samples and data compatibility challenges from using multiple platforms which creates uncertainty in determining whether discrepancies are due to biological factors or errors in measurement. The nCounter Vantage 3D Solid Tumor portfolio enables the simultaneous measurement of DNA, RNA and protein, addressing previous limitations.
The new products expand the portfolio of 3D Biology panels for analyzing solid tumors and FFPE tissue. The nCounter Vantage 3D DNA (SNV) Solid Tumor Panel is designed for highly multiplexed profiling of known cancer mutations, as well as insertions and deletions (INDELs) from as little as 5 nanograms of DNA.
NanoString will host a workshop at ASHG where collaborators from MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center will present data that demonstrate the robustness and sensitivity of the assay across a wide range of FFPE samples. The presentation, “3D Biology™: Simultaneous Single-Molecule Quantification of DNA (SNVs), mRNA, Fusion Genes and Proteins Using Molecular Barcodes,” will be held in Room 10 of the East Building, on Wednesday, October 19th from 1:00–2:30pm Pacific Time.
These new product launches demonstrate NanoString’s continued commitment to expanding the boundaries of biological research through 3D Biology. At the 2016 ASHG Annual Meeting in Vancouver, British Columbia, NanoString will showcase nCounter Vantage 3D Solid Tumor capabilities at booth #512.
For more information, please visit 3d.nanostring.com
For Research Use Only. Not for use in diagnostic procedures.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential to discover new biomarkers, mutations and genetic signatures using the company's nCounter Vantage 3D assays that could lead to the development of diagnostic assays on the nCounter platform, and the potential of such assays to provide key clinical insights that could change patient treatment. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, Prosigna and Vantage 3D are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.